Enprofylline: Difference between revisions
CSV import |
CSV import |
||
| Line 33: | Line 33: | ||
{{stub}} | {{stub}} | ||
== Enprofylline == | |||
<gallery> | |||
File:Enprofylline.svg|Structural diagram of Enprofylline | |||
File:Enprofylline_molecule_spacefill.png|Space-filling model of the Enprofylline molecule | |||
File:Ditolylguanidine_3D_BS.png|3D ball-and-stick model of Ditolylguanidine | |||
</gallery> | |||
Latest revision as of 00:43, 18 February 2025
Enprofylline is a xanthine derivative used in the treatment of asthma, which functions as a bronchodilator. It is less likely to cause cardiovascular and central nervous system side effects compared to theophylline.
Etymology[edit]
The term "Enprofylline" is derived from the chemical name "3-propylxanthine". The prefix "En-" is derived from the propyl group attached to the xanthine molecule.
Pharmacology[edit]
Enprofylline acts as a selective adenosine A2 receptor antagonist, and inhibits phosphodiesterase. Its mechanism of action is not completely understood, but it is known to inhibit the enzyme phosphodiesterase, leading to an increase in intracellular cAMP, relaxation of smooth muscle and inhibition of leukocyte cellular functioning, reduction in inflammation and immune response.
Side Effects[edit]
Enprofylline has fewer side effects compared to theophylline. However, it can still cause nausea, vomiting, headache, and dizziness. In rare cases, it can cause hypotension and arrhythmia.
